Video

Dr. Pegram on Sequencing Therapies in HER2-Positive Breast Cancer

Mark D. Pegram, MD, director, Breast Cancer Oncology Program, Stanford Cancer Institute, discusses contemporary sequencing of therapies for HER2-positive breast cancer.

Mark D. Pegram, MD, director, Breast Cancer Oncology Program, Stanford Cancer Institute, discusses contemporary sequencing of therapies for HER2-positive breast cancer.

It can be challenging to cycle through and properly sequence the targeted therapies for this specific tumor type, Pegram explains. The MARIANNE trial randomized patients to chemotherapy and trastuzumab versus T-DM1 and a placebo versus T-DM1 and pertuzumab, which resembles the regimen from the CLEOPATRA study. Pegram says the efficacy remained similar between the three arms.

However, the superiority endpoint of the T-DM1 plus pertuzumab arm was not met, nor was there any T-DM1 superiority compared to chemotherapy or trastuzumab.

The CLEOPATRA regimen, with pertuzumab in the advanced disease setting, is the preferred regimen for Pegram.

Related Videos
Nirav Shah, MD, MSHP, discusses evaluating zamtocabtagene autoleucel in patients with relapsed/refractory diffuse large B-cell lymphoma.
Bhagirathbhai Dholaria, MBBS
Sairah Ahmed, M.D
Joshua K. Sabari, MD
Barry W. Goy, MD
Fred Saad, CQ, MD, FRCS, FCAHS, director, Prostate Cancer Research, Montreal Cancer Institute, Centre Hospitalier de l’Université de Montréal; full professor, Department of Surgery, Université de Montréal; uro-oncologist, Urology Department, University of Montreal Health Center
MATT WAGAR, MD
Dr Kishtagari on Pelabresib Plus Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis
Manmeet Singh Ahluwalia, MD, MBA, FASCO, chief scientific officer, chief, medical oncology, deputy director, Fernandez Family Endowed Chair in Cancer Research, Baptist Health Miami Cancer Institute
Kelly E. McCann, MD, PhD, assistant professor, breast medical oncologist, UCLA